NEW YORK, Feb 8 (Reuters) - Tetraphase Pharmaceuticals Inc Chief Executive Guy Macdonald said annual sales of the company's lead experimental antibiotic for serious bacterial infections could climb as high as $700 million if approved.
The antibiotic, eravacycline, is being studied in a pivotal 450-patient Phase III trial for intra-abdominal infections. Tetraphase expects to have the data in the fourth quarter, after which it will apply for U.S. approval that could come in 2018.
"The FDA has been very supportive of getting new antibiotics approved, so clearly we have a fast-track agreement with them once we get the positive data," Macdonald told Reuters. (Reporting by Bill Berkrot, editing by G Crosse)